Revenue

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

As Kimco Realty prepares to present at the Raymond James conference, investors are watching for insights into its grocery-anchored retail strategy.

With its fifth straight EcoVadis Platinum rating and deep data transparency, ENNOVI is building a new blueprint for accountability in the industrial sector.

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

Landmark rulings in Canada & the U.S. sanction regulators for misconduct in the MyForexFunds case, raising serious questions about accountability.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.

U.S. Energy Corp. unveils an ambitious plan to merge helium, oil, and carbon capture, but can this small-cap company deliver on its big promises?

Avista posts strong utility earnings but faces hurdles from investment losses and a key customer departure, unveiling a multi-billion dollar grid plan.

Rise Wellness launches its new 30g carbonated protein drink at Costco, betting on fizz and function to capture a rapidly growing, competitive market.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.

The fashion giant's revenue grew 11% in 2025, but net income fell sharply due to acquisition costs, tariffs, and a murky outlook for 2026.

With an $11.75M boost, a new device promises blood results in minutes, not hours, signaling a major pharma player's strategic pivot into diagnostics.

With $400M in 2025 sales, Immunocore now leverages its KIMMTRAK success to fund a high-stakes pivot into broader cancers, HIV, and autoimmune disease.

Ex-Google and Salesforce leader David Keene joins Agentive as Co-Founder, betting on agentic AI to solve the costly complexity of modern B2B sales tools.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

The cold storage giant saw strong cash flow growth in 2025 despite a net loss, but its conservative 2026 forecast signals persistent industry headwinds.